Literature DB >> 19082258

Medicines in Mexico, 1990-2004: systematic review of research on access and use.

Veronika J Wirtz1, Michael R Reich, René Leyva Flores, Anahí Dreser.   

Abstract

OBJECTIVE: To review original research studies published between 1990 and 2004 on the access and use of medicines in Mexico to assess the knowledge base for reforming Mexico's pharmaceutical policy.
MATERIAL AND METHODS: A literature review using electronic databases was conducted of original studies published in the last 15 years about access and use of medicines in Mexico. In addition, a manual search of six relevant journals was performed. Excluded were publications on herbal, complementary and alternative medicines.
RESULTS: Were identified 108 original articles as being relevant, out of 2289 titles reviewed, highlighting four policy-related problems: irrational prescribing, harmful self-medication, inequitable access, and frequent drug stock shortage in public health centers.
CONCLUSIONS: This review identified two priorities for Mexico's pharmaceutical policy and strategies: tackling the irrational use of medicines and the inadequate access of medicines. These are critical priorities for a new national pharmaceutical policy.

Mesh:

Substances:

Year:  2008        PMID: 19082258     DOI: 10.1590/s0036-36342008001000008

Source DB:  PubMed          Journal:  Salud Publica Mex        ISSN: 0036-3634


  8 in total

1.  The fuzzy line between needs, coverage, and excess in the Mexican Formulary List: an example of qualitative market width analysis.

Authors:  Israel Rico-Alba; Albert Figueras
Journal:  Eur J Clin Pharmacol       Date:  2012-10-23       Impact factor: 2.953

2.  Effects of the expansion of doctors' offices adjacent to private pharmacies in Mexico: secondary data analysis of a national survey.

Authors:  Ricardo Pérez-Cuevas; Svetlana V Doubova; Veronika J Wirtz; Edson Servan-Mori; Anahí Dreser; Mauricio Hernández-Ávila
Journal:  BMJ Open       Date:  2014-05-22       Impact factor: 2.692

3.  Supporting the Medication Adherence of Older Mexican Adults Through External Cues Provided With Ambient Displays: Feasibility Randomized Controlled Trial.

Authors:  Ernesto Zárate-Bravo; Marcela D Rodríguez; Juan-Pablo García-Vázquez; Engracia Torres-Cervantes; Gisela Ponce; Ángel G Andrade; Maribel Valenzuela-Beltrán
Journal:  JMIR Mhealth Uhealth       Date:  2020-03-02       Impact factor: 4.773

4.  Prevalence and characterization of undiagnosed arterial hypertension in the eastern zone of Mexico.

Authors:  Silvia Palomo-Piñón; Neftali Eduardo Antonio-Villa; Luis Rey García-Cortés; Cleto Álvarez-Aguilar; Esteban González-Palomo; Olga Margarita Bertadillo-Mendoza; María Eugenia Figueroa-Suárez; Francisco Vargas-Hernández; Imer Guillermo Herrera-Olvera; Jairo Enoc Cruz-Toledo; Maria Adriana Cruz-Arce; Berenice Serafín-Méndez; Gerardo Muñoz-Cortés; Claudia Janeth Morfin-Macias
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-12-28       Impact factor: 3.738

5.  A Participatory Sensing Study to Understand the Problems Older Adults Faced in Developing Medication-Taking Habits.

Authors:  Maribel Valenzuela-Beltrán; Ángel G Andrade; Katarzyna Stawarz; Marcela D Rodríguez
Journal:  Healthcare (Basel)       Date:  2022-07-02

6.  User Perceptions of an mHealth Medicine Dosing Tool for Community Health Workers.

Authors:  Daniel Palazuelos; Assiatou B Diallo; Lindsay Palazuelos; Narath Carlile; Jonathan D Payne; Molly F Franke
Journal:  JMIR Mhealth Uhealth       Date:  2013-04-04       Impact factor: 4.773

Review 7.  Assessing evidence of inequalities in access to medication for diabetic populations in low- and middle-income countries: a systematic review.

Authors:  Yodi Christiani; Teerapon Dhippayom; Nathorn Chaiyakunapruk
Journal:  Glob Health Action       Date:  2016-12-08       Impact factor: 2.640

8.  Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.

Authors:  Daniela Moye-Holz; Jitse P van Dijk; Sijmen A Reijneveld; Hans V Hogerzeil
Journal:  Global Health       Date:  2017-08-01       Impact factor: 4.185

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.